アスペルギロマ を 抗真菌 剤 だけ で 成功 的 に 治療 する: 保守 的 な 治療 の 例
Ad Rian Chong1, Khai Lip Ng1, Nai-Chien Huan2,3,4
1Division of Respiratory Medicine, Department of Internal Medicine Melaka Hospital Melaka Malaysia.
Respirology case reports
|September 2, 2025
まとめ
ボリコナゾールとイサブコナゾールによる抗真菌治療は,手術や栓塞に不適した高齢患者の肺アスペルギロマのサイズを大幅に減らし,症状を改善しました.
科学分野:
- 肺科
- 菌類学
- 感染症
背景:
- 肺アスペルギロマは重症で生命を脅かすような 血症を引き起こす可能性があります
- 標準的な治療法である手術切除と支気管動脈栓塞 (BAE) は,特に高齢者や併発性疾患の患者にとって,重大なリスクを伴う.
- アスペルギロマの自発的な回復は,抗真菌薬のみで稀です.
研究 の 目的:
- 侵襲的処置を拒否した患者の口服抗真菌剤による肺アスペルギロマの治療に成功した症例を報告する.
- 肺アスペルギロマの管理におけるヴォリコナゾールとイサブコナゾールの有効性を評価する.
主な方法:
- 高齢の男性で結核歴があり 左側上葉アスペルギロマによる 血症の報告です
- 患者が手術と BAEを断った リスクの認識から
- 口服用ヴォリコナゾールとイサブコナゾルが6ヶ月間投与された.
主要な成果:
- 患者は臨床改善を経験しました.
- 肺アスペルギロマの大きさの有意な減少は6ヶ月の抗真菌療法で観察されました.
- 治療期間中に重大な有害事象は報告されなかった.
結論:
- 口服用抗真菌剤は,侵襲的な治療に不適合または拒否する肺アスペルギロマの患者にとって有効な治療法である可能性があります.
- 肺アスペルギロマに対する抗真菌単体療法の有効性と安全性を確立するために,さらなる研究が必要である.
さらに関連する動画
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
11.7K
08:01Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
Published on: March 22, 2012
28.1K
関連する概念動画
Pulmonary Tuberculosis V
237
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
237
Endocarditis III: Medical Management
17
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
17
Tonsillitis II: Management
174
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
174
Pneumonia IV: Management
445
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
445
Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
Cystic Fibrosis: Management
222
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
222
